Ms Marian Sloan:

One of the new drug pilots was evaluated. There was great feedback that families, usually families involved in the person's care plan, discussed issues around consent and informed consent and what could and could not be shared. As part of that process, they developed protocols and parameters around what could and would not be shared in order that the person going through it felt safe. The families felt they had much more knowledge about what the process was, what their expectations could be and how they could manage that recovery process for themselves and see the signs much more quickly when the person's recovery talk had gone and they were back into that use of hiding and secretiveness. That worked really well using the framework we already have for interagency work. It is a far-sighted framework.